Healthpeak’s Earnings Call Contradictions: Lease Timing, Outpatient Spread Assessments, and Acquisition Plans Clash

Date of Call: Aug 5, 2026

Financials Results

• EPS: FFO adjusted of 46 cents per share

Guidance:

• Raised FFO adjusted guidance range by $0.02 to $1.73 to $1.77 per share.
• Same-store NOI expected to increase 200 basis points at midpoint, driven by 200 bps improvement in lab and senior housing.
• Anticipate modest improvement in lab total occupancy by year-end from June 30th level.
• Outpatient leasing pipeline suggests internal growth will accelerate in 2027.

Business Commentary:

Outpatient Medical Performance:

• HealthPeak Properties reported cash re-leasing spreads of 5% for the outpatient medical segment in Q2 2026, in line with their 10-quarter average and above pre-merger averages of 2% to 3%.
• Total occupancy in outpatient medical increased by 20 basis points sequentially to 90.7%.
• The strong performance is attributed to continued demand for their real estate and effective leasing strategies, with significant contributions from partnerships like Northside in Atlanta.

Life Science (Lab) Segment Recovery:

• The lab segment achieved 78.5% total occupancy, reflecting an 80 basis points sequential increase and a 140 basis points increase since year-end 2025.
• Executed 381,000 square feet of leases in Q2, with about 60% being new leasing and 30% on vacant space.
• The recovery is driven by strong leasing pipeline and net absorption, with a focus on capturing market demand in core sub-markets like San Diego's Torrey Pines.

Senior Housing Growth:

• HealthPeak's ownership interest in Janus Living increased to 74%, representing approximately $6.5 billion in equity value.
• Janus Living reported 45% total revenue growth and 34% adjusted EBITDA growth for Q2.
• Growth is supported by an active acquisition pipeline and a successful business plan execution, leading to a significant increase in portfolio size and operating partners.

Capital Recycling and Strategic Partnerships:

• HealthPeak completed $1 billion in acquisitions and buybacks, with plans to generate $1.9 billion in gross proceeds from capital recycling initiatives by year-end.
• The company formed strategic partnerships with Blackstone and Brookfield, enhancing access to alternative equity capital.
• The Brookfield transaction specifically allowed HealthPeak to maintain control while raising capital, exemplifying their strategic approach to capital allocation.

Balance Sheet Strength:

• The company reported a net debt to EBITDA ratio of 4.7 times and has $4.1 billion in available liquidity.
• Leverage is below five times, providing flexibility for future capital allocation and investment opportunities.
• This strong balance sheet is a result of prudent debt management and significant proceeds from capital recycling initiatives.

Sentiment Analysis:

Overall Tone: Positive

• Management emphasizes a 'winning mindset,' stating 'demand exceeds supply and fundamentals are in your favor.' They highlight strong balance sheet, successful joint ventures with Blackstone and Brookfield, and progress in outpatient and lab leasing. Specific quotes: 'We're stronger because of it,' 'The building blocks are in place for occupancy in the sector to inflect, led by HealthPeak,' and 'We've made significant progress across the business through the first half of the year.'

Q&A:

• Question from Ronald Camden (Morgan Stanley): When do you think you'll have line of sight to see same store inflect to the positive?
  Response: Management focuses on total occupancy and NOI growth over same-store metrics; they improved lab same-store guidance by 200 bps and are trending in the right direction, but it's too soon to predict the exact quarter of inflection.

• Question from Juan Sanabria (BMO Capital Markets): Any changes in the rate environment, free rent, build-out costs, or tenant size in lab leasing?
  Response: Pipeline remains robust with disproportionately wet lab space; rates are in line with averages, free rent is 1-2 months per year, and tenant sizes are normalizing to $25k-$75k throughput range.

• Question from John Kilachowski (Wells Fargo): Is the distressed lab opportunity looking more attractive, and what's the opportunity set?
  Response: HealthPeak is focused on core markets and buildings where its platform can add value, leasing up vacant spaces; the team is working on several situations and expects to be a consolidator over the next 24 months.

• Question from Austin Werschmitt (KeyBank Capital Markets): Can you provide details on leased vs. occupied space and commencement schedules?
  Response: Commencements in the back half of the year exceed expirations; the company expects modest occupancy improvement by year-end and has potential 2026 commencements from recent LOIs.

• Question from Seth Bergy (Citi): How has the conversion timeline for lab leasing changed given market activity?
  Response: Conversion timelines remain relatively consistent (3-9 months) as tenants are still cautious, though the pipeline is healthy and the company is capturing demand.

• Question from Connor Mitchell (UBS): Can you expand on capex for second-generation leasing and expected costs?
  Response: Capital costs are generally modest, around 10-25% for renewals/new leasing; development assets may require elevated capital for modernization but the portfolio has minimal shell space.

• Question from Rich Anderson (Cantor Fitzgerald): Is the 100 bps total occupancy improvement for lab still in the range of possible for the full year?
  Response: The company has already captured the 100 bps improvement from the prior year's 77% occupancy and expects modest further improvement by year-end, with some lumpiness due to timing of expiries.

• Question from Rich Hightower (Barclays): Why did outpatient cash spreads decelerate, what's the mark-to-market opportunity, and are you looking to grow the portfolio via JVs?
  Response: Releasing spreads are still strong at +5%, up 50% from the last decade; low TIs and 3% escalators are key; the company is pleased with results and sees growth opportunities, including through JVs.

• Question from Farrell Granath (Bank of America): What led to the Brookfield transaction structure, and what's the appetite for more JVs?
  Response: The Brookfield deal provides a 51% ownership, strong upfront cash, and a call option for future buyback at a favorable return; the company expects to do more JVs with both Brookfield and Blackstone, leveraging its platform and balance sheet.

• Question from Michael Carroll (RBC Capital Markets): What are the most interesting lab markets for acquisitions, and what deal structures are you considering?
  Response: Focus is on core markets like Bay Area, San Diego, and Boston where the company can add value; deal structures are predominantly fee simple, though some loan structures with options to buy may still be considered.

• Question from Michael Stroyek (Green Street): Which lab markets are seeing the strongest demand and where is pricing power holding up best?
  Response: Strongest demand is in Bay Area and San Diego; pricing power is better in non-widely marketed deals, especially in Boston where the company's assets are well-leased despite market challenges.

• Question from Mike Mueller (JPMorgan): Was there anything out of the ordinary driving weaker lapse rent spreads in outpatient?
  Response: The slight spread decline was driven by a single competitive renewal lease in Boston; overall portfolio mark-to-market is stable with positive spreads, and the company remains pleased with leasing results.

Contradiction Point 1

Timing of Lease Commercements and Future Pipeline Focus

Contradiction on when most new leases will commence.

What are the key factors driving the company's recent financial performance? - Austin Werschmitt (KeyBank Capital Markets)

2026Q2: While some leases in the LOI pipeline could commence in 2026, the focus remains on capturing demand throughout the year with no pressure to meet specific quarterly targets. - Kelvin

"Given that about 30% of new lab leasing was for vacant space, can you discuss the difference between leased and occupied space, recent trends, and the commencement schedule for signed leases?" - Austin Werschmidt (KeyBanc Capital Markets)

2026Q2: Some leases could commence in 2026/2027, but most pipeline is for 2027 and beyond. - Kelvin Loong

Contradiction Point 2

Outpatient Cash Re-Leasing Spread Performance

Contradiction on whether a recent quarter was an outlier or indicative of a broader trend.

Rich Hightower (Barclays) - Rich Hightower (Barclays)

2026Q2: While cash spreads were down slightly, they remain strong at +5%, up 50% from the last decade... representing a phenomenal result in the business. - Mark

Okay, let me tackle this. The user wants me to rewrite the input into one concise earnings-call question. The input is: "In outpatient medical, cash spreads decelerated slightly in Q2. What drove that, what's the mark-to-market opportunity, and are you looking to grow the portfolio via JVs?" First, I need to identify the main points. The original input has three parts: the cause of the deceleration in cash spreads, the mark-to-market opportunity, and growth via JVs. But the user wants a single question.The main topic here is the deceleration in cash spreads in outpatient medical during Q2. The follow-up questions are about the reasons, opportunities, and growth strategies. However, combining all into one question might be too long. The challenge is to condense it into one clear question without losing the essence.The original input isn't a single question but three. The task is to form one question. The key is to focus on the primary issue: what drove the deceleration in cash spreads. The other parts (mark-to-market and JVs) can be omitted if necessary to keep it concise, but maybe they can be integrated.But according to the rules, if the input is not a question or too vague, output as-is. However, the input is a question (starts with "What drove that..."), so it's a valid question. But the user wants it rewritten into one concise question. Let me try to combine the elements.Possible rewrite: "What factors contributed to the slight deceleration in outpatient medical cash spreads in Q2, and what growth opportunities or joint venture plans exist for the portfolio?" Wait, but the original asks three things. Maybe the user wants to focus on the main question (what drove the deceleration) and combine the others. However, the instruction says to form one question. The original input is three questions. The user might want to merge them into one. Let me check the rules again: output exactly one line, only the final question text, ending with a question mark if possible.So, the input is three questions. The task is to make one. The main question is about the cause of the deceleration. The other parts are about mark-to-market and JVs. Maybe combine into: "What factors contributed to the slight deceleration in outpatient medical cash spreads in Q2, and what are the mark-to-market opportunities and growth strategies, including joint ventures, for the portfolio?" But that's a bit long. Let me check if it's concise. Alternatively, focus on the first part and the last part about JVs. Maybe: "What factors caused the slight deceleration in outpatient medical cash spreads in Q2, and are there plans to grow the portfolio through joint ventures?" That's two parts but still one question. The mark-to-market opportunity is omitted. However, the original input has three questions. The user might need to prioritize the main ones. The key is to make it one concise question. Maybe the best approach is to ask about the cause and the growth via JVs. The mark-to-market might be too detailed. Alternatively, combine all into one: "What factors drove the slight deceleration in outpatient medical cash spreads in Q2, what mark-to-market opportunities exist, and are there plans to grow the portfolio through joint ventures?" But the user wants it concise. The original input has three questions. The user might prefer the first and the last. However, the instruction is to make one question. Maybe the answer is to combine into one question that covers all aspects but is concise. Let me check the example. The original input is three questions. The user wants to merge into one. The example in the problem might have a similar case. The correct approach is to form a single question that captures the essence. The main point is the deceleration in cash spreads. The other parts are additional inquiries. So, the concise question would be: "What factors contributed to the slight deceleration in outpatient medical cash spreads in Q2, and what growth opportunities or joint venture plans exist for the portfolio?" But I need to check if that's acceptable. The original input's three questions are about cause, mark-to-market, and JVs. The rewritten question combines cause and growth opportunities (including JVs). The mark-to-market is omitted. But maybe it's too much to include all three. The user might prefer a single question that's concise. Alternatively, the mark-to-market could be part of the growth opportunities. So the final question would be: "What factors caused the slight deceleration in outpatient medical cash spreads in Q2, and what are the associated mark-to-market opportunities and plans for portfolio growth through joint ventures?" This includes all three elements but is still one question. However, it's a bit long. The user might prefer brevity. The key is to make sure it's one question. The output must end with - Mike Mueller (J.P. Morgan)

2026Q2: The lower spread was due to one large competitive lease... It was an outlier quarter; the overall portfolio remains strong. - Scott Brinker

Contradiction Point 3

Timing and Expectations for Same-Store NOI and Occupancy

Guidance on when same-store NOI will turn positive and occupancy targets appears inconsistent.

Ronald Camden (Morgan Stanley) - Ronald Camden (Morgan Stanley)

2026Q2: While it's too soon to predict the exact quarter, the company has already improved its lab same-store guidance by 200 basis points at the midpoint. - Kelvin and Scott Brinker(CEO)

For the lab portfolio, with sequential occupancy growth and further improvement expected in the back half, when will you have line of sight for same-store NOI to turn positive? - Farrell Granath (BofA Securities)

2026Q1: The company is currently focused on completing its planned capital recycling and acquisitions ($1 billion each) before considering additional opportunistic investments in life science. - Scott Brinker(CEO)

Contradiction Point 4

Outlook on Distressed Lab Opportunities and Capital Recycling

Statements on the company's focus and capacity for further acquisitions show a shift.

John Kilachowski (Wells Fargo) - John Kilachowski (Wells Fargo)

2026Q2: The company expects to be a consolidator over the next 24 months and is working on several potential deals. - Scott Brinker(CEO)

What is the current outlook and opportunity set for distressed lab opportunities? - Farrell Granath (BofA Securities)

2026Q1: The company is currently focused on completing its planned capital recycling and acquisitions ($1 billion each) before considering additional opportunistic investments in life science. - Scott Brinker(CEO)

Contradiction Point 5

Lab Occupancy and Same-Store NOI Outlook

Outlook for occupancy improvement and related financials shifts from a measured expectation to an accelerated, more optimistic projection.

Rich Anderson (Cantor Fitzgerald) - Rich Anderson (Cantor Fitzgerald)

2026Q2: The company has already exceeded the 100 bps target from the previous 77% occupancy level. While there may be lumpiness due to timing of lease expiries, modest further improvement through year-end is expected, providing room for incremental occupancy. - Kelvin(CFO)

Given the strong first-half performance, is the previously guided 100 bps full-year occupancy increase in the lab still achievable, or is a give-back possible? - Nicholas Yulico (Scotiabank Global Banking and Markets)

2025Q4: The company expects improvement by year-end 2026, assuming positive capital markets trends continue. - Scott Brinker(CEO)